An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
Latest Information Update: 02 Feb 2024
At a glance
- Drugs YY 201 (Primary)
- Indications Acute myeloid leukaemia; Advanced breast cancer; Carcinoma; Haematological malignancies; Head and neck cancer; Large granular lymphocytic leukaemia; Liver cancer; Male breast cancer; Pancreatic cancer; Peripheral T-cell lymphoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Yuyu
Most Recent Events
- 31 Jan 2024 Quite confusing to add stages for Hematological Malignancies, hence not tagged please update further.
- 31 Jan 2024 New trial record